About: The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria
Creator	Burkhard, Peter Corradin, Giampietro Nebie, Issa Doll, Tais Karch, Christopher Lanar, David Paulillo, Sara
Source	PMC
abstract	BACKGROUND: The parasitic disease malaria remains a major global public health concern and no truly effective vaccine exists. One approach to the development of a malaria vaccine is to target the asexual blood stage that results in clinical symptoms. Most attempts have failed. New antigens such as P27A and P27 have emerged as potential new vaccine candidates. Multiple studies have demonstrated that antigens are more immunogenic and are better correlated with protection when presented on particulate delivery systems. One such particulate delivery system is the self-assembling protein nanoparticle (SAPN) that relies on coiled-coil domains of proteins to form stable nanoparticles. In the past we have used de novo designed amino acid domains to drive the formation of the coiled-coil scaffolds which present the antigenic epitopes on the particle surface. RESULTS: Here we use naturally occurring domains found in the tex1 protein to form the coiled-coil scaffolding of the nanoparticle. Thus, by engineering P27A and a new extended form of the coiled-coil domain P27 onto the N and C terminus of the SAPN protein monomer we have developed a particulate delivery system that effectively displays both antigens on a single particle that uses malaria tex1 sequences to form the nanoparticle scaffold. These particles are immunogenic in a murine model and induce immune responses similar to the ones observed in seropositive individuals in malaria endemic regions. CONCLUSIONS: We demonstrate that our P27/P27A-SAPNs induce an immune response akin to the one in seropositive individuals in Burkina Faso. Since P27 is highly conserved among different Plasmodium species, these novel SAPNs may even provide cross-protection between Plasmodium falciparum and Plasmodium vivax the two major human malaria pathogens. As the SAPNs are also easy to manufacture and store they can be delivered to the population in need without complication thus providing a low cost malaria vaccine.
has issue date	2017-09-06(xsd:dateTime)
bibo:doi	10.1186/s12951-017-0295-0
bibo:pmid	28877692
has license	cc-by
sha1sum (hex)	df753ddb66629cfd0795d0ffa319caa0440de284
schema:url	https://doi.org/10.1186/s12951-017-0295-0
resource representing a document's title	The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria
has PubMed Central identifier	PMC5588597
has PubMed identifier	28877692
schema:publication	J Nanobiotechnology
resource representing a document's body	covid:df753ddb66629cfd0795d0ffa319caa0440de284#body_text
is schema:about of	named entity 'PROTEIN ' named entity 'Multiple' named entity 'target' named entity 'coiled-coil domain' named entity 'VACCINE' covid:arg/df753ddb66629cfd0795d0ffa319caa0440de284 named entity 'FORMATION' named entity 'VACCINE' named entity 'COILED-COIL DOMAIN' named entity 'POTENTIAL' named entity 'P27' named entity 'TO FORM' named entity 'TO PREVENT' named entity 'SCAFFOLDS' named entity 'FAILED' named entity 'DRIVE' named entity 'DELIVERY SYSTEMS' named entity 'PROTECTION' named entity 'PRESENT' named entity 'CONCERN' named entity 'MULTIPLE' named entity 'IMMUNOGENIC' named entity 'CONSTRUCT' named entity 'USE OF' named entity 'MALARIA' named entity 'NANOPARTICLE' named entity 'PROTEIN ' named entity 'ASEXUAL BLOOD STAGE' named entity 'PRESENTED' named entity 'BETTER' named entity 'EFFECTIVE' named entity 'TARGET' named entity 'APPROACH' named entity 'GLOBAL' named entity 'DE NOVO' named entity 'ANTIGENS' named entity 'DELIVERY SYSTEM' named entity 'CLINICAL SYMPTOMS' named entity 'COILED-COIL' named entity 'STABLE' named entity 'CORRELATED' named entity 'MALARIA' named entity 'STUDIES' named entity 'NANOPARTICLE' named entity 'PARTICULATE' named entity 'HAVE' named entity 'RESULTS' named entity 'IN THE PAST' named entity 'EPITOPES' named entity 'USED' named entity 'PARASITIC DISEASE' named entity 'AMINO ACID' named entity 'SURFACE' named entity 'PUBLIC HEALTH' named entity 'DEMONSTRATED' named entity 'BACKGROUND' named entity 'A MAJOR' named entity 'PARTICLE' named entity 'DEVELOPMENT' named entity 'MALARIA VACCINE' named entity 'PROTEINS' named entity 'P. FALCIPARUM' named entity 'SPECIFIC' named entity 'NEW' named entity 'NANOPARTICLES' named entity 'remains' named entity 'nanoparticles' named entity 'presented' named entity 'de novo' named entity 'domains' named entity 'stable' named entity 'coiled-coil' named entity 'vaccine' named entity 'protein' named entity 'malaria vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software